EMA publishes draft guideline on biosimilar insulin products

December 19, 2012 6:15 AM

European Medicines Agency (EMA), the pioneer in the development of biosimilars, issued a new draft guideline for biosimilar insulin products and waiting for public comments till the end of June 2013.

The draft guideline, “Non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues” was published at the end of last week and can be reached from here.

The guideline on development of biosimilar human insulin and insulin analogues was first finalized and approved in February 2006 in the European Union. In November 2012, EMA’s Biosimilar Medicinal Products Working Party (BMWP) released a draft revision of the policy, which was adopted by the CHMP on 13 December and released to the public last Friday.

 

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!